Close Menu

NEW YORK (GenomeWeb) – Cepheid announced today that it has received clearance from the US Food and Drug Administration for its Xpert MRSA NxG, a test for methicillin-resistant Staphylococcus aureus (MRSA) infection.

The test runs on the GeneXpert molecular diagnostic system and delivers results in around an hour, the company noted. To develop the test, Cepheid used an extensive library of MRSA strains collected around the world, and it included updated PCR primers and probes that detect both mecA and mecC strains, which reduces the frequency of false-positive results.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Apr
23
Sponsored by
N-of-One

In 2016, the Association for Molecular Pathology (AMP), in partnership with the College of American Pathologists (CAP) and American College of Molecular Genetics (ACMG), launched a set of guidelines meant to set industry standards for reporting of molecular diagnostic test results in oncology, using a tier-based system and defined levels of evidence. 

Apr
24
Sponsored by
Biocrates

This webinar will provide a wide-ranging overview of the promise for metabolomics in studying human health and disease, as well as its potential for integration with other -omics disciplines.

Apr
30
Sponsored by
Lexogen

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

May
08
Sponsored by
Sysmex Inostics

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.